Agoracom Blog Home

Posts Tagged ‘Medical Marijuana stocks’

« Older Entries

Empower $EWP Announces Updates to AI Pilot Program $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM-JC at 8:14 AM on Tuesday, March 19th, 2019
  • Empower in partnership with Canntop AI has commenced preliminary testing and analysis to identify key insights for improvements to physician recommended treatment plans
  • Company has provided select SEO terms and phrases for use in Canntop’s artificial intelligence platform, targeting two key company markets, Portland, OR and Phoenix, AZ,

VANCOUVER, March 19, 2019 – EMPOWER CLINICS INC. (CSE: EPW) (Frankfurt: 8EC) (“Empower” or the “Company“), a growth oriented and diversified medical cannabis company, is pleased to provide an update on recent activities by the technical teams at Empower and Canntop AI Inc. (“Canntop“), a subsidiary of Datametrex AI Limited (“Datametrex“) to develop a deeper understanding of patient awareness of cannabis-based treatment options and ongoing effectiveness of treatment programs.

The Company has provided select SEO terms and phrases for use in Canntop’s artificial intelligence (“AI“) platform, targeting two key company markets, Portland, OR and Phoenix, AZ, to gain actionable insights on how consumer social data is generating interest in CBD-based products, alternative pain management options and the use of cannabis-based therapies.  

“Insights derived from AI are beginning to demonstrate how patients in our key markets are talking about or describing their experience and ideas related to cannabis/CBD-based treatments, and even suggesting recommendations about alternative therapies and their effectiveness in treating a wide array of qualifying conditions,” stated Steven McAuley, Empower’s Chief Executive Officer.

“We believe the outcomes of our AI efforts, if successful, could position the Company as an educational leader and we plan to collaborate with the industry with the ultimate goal of improving patient care,” said Mr. McAuley. “Canntop’s powerful AI tools are helping us analyze the substantial amounts of data in the Empower database and we expect will facilitate the integration of the additional data we expect to derive from the proposed acquisition of the Sun Valley Clinic group, that has a combined 165,000 patients.”

“We are thrilled that Empower chose Canntop AI to be their partner for their Artificial Intelligence needs. This is a great validation for our business model and we look forward to expanding our program with Empower as they continue to expand their product. We believe that this alliance between Canntop and Empower will create a strong platform for data analysis in the cannabis sector especially in the U.S., providing insurers and health care providers an ideal solution for patient care,” said Michael Frank, Chief Strategy Officer of Datametrex.

EMPOWER TECHNOLOGY

  • Patient EHR and Management System Empower utilizes a market-leading patient electronic management and POS system that is HIPAA compliant and provides deep insight to patient care.
  • Tele-Medicine Platform The Company supports remote patients using its tele-medicine portal, enabling patients who do not live near one of its clinic locations, or are disabled or unable to come to a location, to still benefit from a doctor consultation.
  • Website and e-commerce Empower will be commencing the development of its new corporate website and e-commerce store to promote and sell its growing line of CBD-based products under the Sollievo brand and other partner brands.

ABOUT EMPOWER

Empower is a leading owner/operator of a network of physician-staffed clinics focused on helping patients improve and protect their health through innovative uses of medical cannabis. It is expected that Empower’s proprietary product line “Sollievo” will offer patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine, and an expanded product development strategy, Empower is undertaking new growth initiatives to be positioned as a vertically integrated, diverse, market-leading service provider for complex patient requirements in 2019 and beyond.

About Datametrex

Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com) and  Implementing Blockchain technology for secure Data Transfers through its investee company, Graph Blockchain (www.graphblockchain.com).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the proposed acquisition of Sun Valley; the expected benefits to be derived from use of the Canntop AI tools; the ability of Canntop’s software to assist in integrating Sun Valley data (assuming the successful completion of such transaction); the benefits of CBD based products; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Canntop software may not be able to properly analyze the Company’s information as is expected or at all; that the proposed acquisition of Sun Valley may not be completed on the terms expected or at all; that regulatory proceedings may negatively impact the Company’s business; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE Empower Clinics Inc.

View original content: http://www.newswire.ca/en/releases/archive/March2019/19/c6623.html

Investors: Steve Low, Boom Capital Markets, [email protected], 647-620-5101; Investors: Steven McAuley, CEO, [email protected], 604-789-2146Copyright CNW Group 2019

Tags: , , , ,
Posted in Empower Clinics Inc. | Comments Off on Empower $EWP Announces Updates to AI Pilot Program $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp. $APP.ca $PNP.ca $ZC.ca

Posted by AGORACOM-JC at 10:13 AM on Thursday, November 16th, 2017

Threed capital

  • Acquired ownership and control of an aggregate of 2,000,000 common shares and 2,000,000 common share purchase warrants of Global Cannabis Applications Corp. 
  • Represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis

TORONTO, Nov. 16, 2017 – ThreeD Capital Inc. ( “ThreeD”) (CSE:IDK) is pleased to announce that it has acquired ownership and control of an aggregate of 2,000,000 common shares (the “Subject Shares”) and 2,000,000 common share purchase warrants (the “Subject Warrants” and together with the Subject Shares, the “Subject Units”) of Global Cannabis Applications Corp. (“Global Cannabis”) on November 15, 2017.  The Subject Units represented approximately 3.7% of all issued and outstanding common shares of Global Cannabis as of November 15, 2017 immediately following the transaction described above (or approximately 7.2% on a partially diluted basis, assuming exercise of the Subject Warrants only), resulting in a corresponding increase in the percentage of shares held by ThreeD and its Joint Actor as a result of the transaction.

Immediately before the transaction described above, ThreeD and the Joint Actor held an aggregate of 2,850,000 common shares of the Company (the “Pre-Closing Shares”), representing approximately 5.5% of the issued and outstanding common shares of the Company.  Of this total, ThreeD held an aggregate of 1,000,000 of the Pre-Closing Shares (representing approximately 1.9% of the issued and outstanding common shares of the Company), and the Joint Actor held an aggregate of 1,850,000 of the Pre-Closing Shares (representing approximately 3.6% of the issued and outstanding common shares of the Company).

Immediately following the transaction described above, ThreeD and the Joint Actor held an aggregate of 4,850,000 common shares (the “Post-Closing Shares”) and convertible securities entitling ThreeD and the Joint Actor to acquire an additional 2,000,000 common shares of the Company (the “Post-Closing Convertible Securities”), representing approximately 9.0% of the issued and outstanding common shares of the Company (or approximately 12.3% assuming exercise of such Post-Closing Convertible Securities only).  Of this total, ThreeD held an aggregate of 3,000,000 of the Post-Closing Shares and 2,000,000 of the Post-Closing Convertible Securities (representing approximately 5.6% of the issued and outstanding common shares of the Company, or approximately 9.0% assuming exercise of such Post-Closing Convertible Securities only), and the Joint Actor held an aggregate of 1,850,000 of the Post-Closing Shares and nil of the Post-Closing Convertible Securities (representing approximately 3.4% of the issued and outstanding common shares of the Company).

The Subject Units were acquired in a private placement and not through the facilities of any stock exchange.  The holdings of securities of Global Cannabis by ThreeD and the Joint Actor are managed for investment purposes, and ThreeD and the Joint Actor could increase or decrease their investments in Global Cannabis at any time, or continue to maintain their current investment position, depending on market conditions or any other relevant factor. The aggregate consideration payable for the Subject Units was $200,000, or $0.10 per Subject Unit.

The trade was effected in reliance upon the exemption contained in Section 2.3 of National Instrument 45-106 on the basis that each of ThreeD and the Joint Actor is an “accredited investor” as defined herein.

About ThreeD Capital Inc.

ThreeD Capital Inc. is a publicly-traded Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources, Artificial Intelligence and Blockchain sectors.

ThreeD seeks to invest in early stage, promising companies where it may be the lead investor and can additionally provide investees with advisory services, mentoring and access to the Company’s network in order to earn increases to the Company’s equity stake.

For further information:
Gerry Feldman, CPA, CA
Chief Financial Officer and Corporate Secretary
[email protected]
Phone: 416-606-7655

Tags: , , , , , , , ,
Posted in Featured, ThreeD, ThreeD Capital | Comments Off on ThreeD Capital Inc. $IDK.ca Acquires Securities of Global Cannabis Applications Corp. $APP.ca $PNP.ca $ZC.ca

Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 8:45 AM on Thursday, February 23rd, 2017

Tbp large

  • Announces launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers
  • Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination

OTTAWA, ONTARIO–(Feb. 23, 2017) – PhytoPain Pharma (PPP), a subsidiary of Tetra BioPharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce the launch of its Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers.

The Phase I clinical research is a classical pharmaceutical study in the development of a new drug. The trial activities will occur over a 3 to 4-month period and involve site initiation, subject recruitment and enrolment, a single daily ascending dose phase and a 7-day multiple daily ascending dose phase, followed by study termination. Algorithme Pharma has already begun recruiting subjects for the Phase I trial. This study is a pivotal safety trial as it will allow Tetra to understand the adverse effects of smoking Cannabis and associate the outcomes, such as cognitive function, to plasma levels of THC and CBD. The study will provide Tetra with the data necessary to discuss with Health Canada and FDA the potential risks in patient populations and discuss marketing requirements for specific indications.

The pharmacokinetic profile and safety data generated by the Phase I trial will allow Tetra to finalize the design of its Phase II-III clinical trial that will assess the safety and efficacy of PPP001 in cancer patients with uncontrolled pain. PPP001 is being developed for cancer patients with moderate-to-severe pain and that are not adequately controlled with the standard of care. Approximately 50% of cancer patients suffer from pain and more than 600,000 of these patients suffer from moderate-to-severe pain. In the USA, there are over 4 million cancer patients and this pain market is valued at over $5 billion USD.

“We are very pleased to announce that the start of the Phase I clinical trial activities as this keeps the company on track in its development of PPP001″, commented Mr, Andre Rancourt. “With PPP001 and the mucoadhesive AdVersa® controlled-release tablet, Tetra is positioning itself to become a major player in the cancer pain therapy market,“ added Mr. Rancourt.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

 

Tags: , , , ,
Posted in All Recent Posts, Featured, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma Announces the Initiation of its Phase I Trial of dried Cannabis $TBP.ca

INTERVIEW: Tetra Bio-Pharma Developing Pharma Derived From Cannabis and Other Medicinal Plants $TBP.ca

Posted by AGORACOM-JC at 11:41 AM on Tuesday, November 8th, 2016

Pharmaceutical Division – PhytoPain Pharma

  • Developing and commercialization of botanical based pharmaceuticals
  • Engaged in the development of medication to alleviate symptoms related to: Pain, Insomnia, anxiety disorder, in patients suffering from Cancer and other, chronic and terminal diseases

Recent Highlights

  • Signed a Supply Agreement with Access to Cannabis for Medical Purpose Regulations (“ACMPR”) licensed producer Aphria Inc.
  • For the supply of dried medical cannabis as an Active Pharmaceutical Ingredient (API) for PPP’s inhalation cannabis product PPP001
  • Acquired multiple intellectual property assets related to the initiation of manufacturing and distribution of products for natural health care including products containing extracts or oils derived from Cannabis sativa
  • Recently announced awarding of the NSERC Engage partnership grant with McGill University will allow AGTK to achieve its commercial strategy to launch Cannabis-derived supplements that comply with the existing regulations regarding cannabis and cannabinoid content

Hub On AGORACOM / Corporate Profile / Watch Interview

Tags: , , ,
Posted in AGORACOM Via Satellite, Medical Marijuana Stocks | Comments Off on INTERVIEW: Tetra Bio-Pharma Developing Pharma Derived From Cannabis and Other Medicinal Plants $TBP.ca

FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals From Cannabis and Other Medicinal Plants $GCI.ca

Posted by AGORACOM-JC at 3:52 PM on Wednesday, August 10th, 2016 


Growpros_hub_large


Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants


Comprised Of Two Divisions


Pharmaceutical Division – PhytoPain Pharma


    

  • A new subsidiary created June 2, 2016. 80% Ownership
    • 

  • Mission is the development and commercialization of botanical based pharmaceuticals
    • 

  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    
Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases
    • 



Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs


    

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
    • 



    

  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products
    • 



WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS


    

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
    • 

  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
    • 

  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products
    • 



PRODUCT PIPELINE


Insomnia Management For Patients With Chronic Pain


    

  • Licensed a hypnotic drug from Mondias Naturals Inc
    • 

  • Management of Insomnia in patients with chronic pain
    • 

  • Currently in late stage Phase III clinical testing
    • 



PhytoPain To Produce A Combination Product


    

  • Proprietary combination expected to reach Phase I clinical testing in 2017
    • 

  • Will be ready for market in 2017 due to combination with Mondias Naturals product
    • 



Pain Management – Inhalation Cannabis Drug Product


    

  • A prescription drug for management of uncontrolled pain in cancer patients
    • 

  • Health Canada will provide guidance during Phase I clinical trial
    • 

  • Commencing December 2016. Anticipating 3-5 year product development
    • 



A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.


OPERATIONS OVERVIEW – MMPR


MMPR Division – Collaboration Agreement


    

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
    • 

  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
    • 



    

  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
    • 



    

  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller
    • 



12 Month Stock Chart








Tags: , , , 
 Posted in AGORACOM Client Feature, All Recent Posts, GrowPros Cannabis Ventures Inc. | Comments Off on FEATURE: GrowPros (GCI:CSE) Natural Pharmaceuticals From Cannabis and Other Medicinal Plants $GCI.ca









 CLIENT FEATURE: GrowPros (GCI: CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca




Posted by AGORACOM-JC
at 4:37 PM on Wednesday, July 27th, 2016 






Growpros_hub_large


Comprised Of Two Divisions


Pharmaceutical Division – PhytoPain Pharma


    

  • A new subsidiary created June 2, 2016. 80% Ownership
    • 

  • Mission is the development and commercialization of botanical based pharmaceuticals
    • 

  • A clinical stage drug development company engaged in the development of medication to alleviate symptoms related to: Pain,
    
Insomni, anxiety disorder, in patients suffering from Cancer and othe, chronic and terminal diseases
    • 



Dr Guy Chamberland, Chief Scientific Officer and Regulatory Affairs


    

  • Professor of herbal medicine and clinical research at the École d’Enseignement Supérieur de Naturopathie du Québec.
    • 



    

  • 22 years’ experience in the pharmaceutical and natural product industries includes successful development of intellectual property for several botanical drug products
    • 



WHY DOCTORS NEED PHARMA MARIJUANA SOLUTIONS


    

  • A Physician’s decision to prescribe a new drug or even a natural health product has to be based on Evidence-Based Medicine > A legal, ethical requirement
    • 

  • Currently, no body of evidence exists to not support the prescription or recommendation of medical marijuana in any medical condition, including terminal cancer
    • 

  • The GrowPros pharmaceutical product development plan would provide the data necessary for physicians to prescribe or recommend our products
    • 



PRODUCT PIPELINE


Insomnia Management For Patients With Chronic Pain


    

  • Licensed a hypnotic drug from Mondias Naturals Inc
    • 

  • Management of Insomnia in patients with chronic pain
    • 

  • Currently in late stage Phase III clinical testing
    • 



PhytoPain To Produce A Combination Product


    

  • Proprietary combination expected to reach Phase I clinical testing in 2017
    • 

  • Will be ready for market in 2017 due to combination with Mondias Naturals product
    • 



Pain Management – Inhalation Cannabis Drug Product


    

  • A prescription drug for management of uncontrolled pain in cancer patients
    • 

  • Health Canada will provide guidance during Phase I clinical trial
    • 

  • Commencing December 2016. Anticipating 3-5 year product development
    • 



A recent discussion with the Quebec College of Physicians confirms that pharmaceutical development of a medical marijuana for inhalation would be well received by the medical community.


OPERATIONS OVERVIEW – MMPR


MMPR Division – Collaboration Agreement


    

  • March 18, 2016 – Signed agreement with Delta 9 Bio-Tech, a “Licensed Producer”
    • 

  • Delta 9 will submit to Health Canada an Amendment to collaborate on GrowPros previous application for facility in Southern Quebec; Amendment submission anticipated by June 30, 2106, Health Canada response anticipated August 30, 2016
    • 



    

  • Key Benefits of Delta 9 Collaboration: Significant process clarity, High probability of success eliminates spec construction risk, Single customer through option to acquire all dried marijuana product for 2 years
    • 



    

  • Key strategic benefit to GrowPros; Controlled production, quality and supply for Pharma Division, Value of license, Wholesale seller vs. retail seller
    • 



Hub On AGORACOM /Corporate Profile 




Tags: , , , 
 Posted in AGORACOM Client Feature, All Recent Posts, GrowPros Cannabis Ventures Inc. | Comments Off on CLIENT FEATURE: GrowPros (GCI: CSE) Natural Pharmaceuticals Derived From Cannabis and Other Medicinal Plants $GCI.ca









 Enertopia Provides Canadian Medical Marihuana Update




Posted by AGORACOM-JC
at 11:00 AM on Friday, June 12th, 2015 








    

  • Signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610
    • 

  • Burlington MMPR license application will continue in the application process under new ownership
    • 

  • Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program
    • 





















VANCOUVER, BC / June 12 2015 – Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) announces updates with respect to the Burlington and The Green Canvas Joint Ventures.


Enertopia has signed a binding LOI to sell its wholly owned sub Thor Pharma Corp along with the MMPR application number 10MMPR0610. The Burlington MMPR license application will continue in the application process under new ownership. The Joint Venture could receive up to $1,500,000 in milestone payments upon the Burlington facility becoming licensed under the MMPR program. These monies would be split approximately 50% with Lexaria Corp. Subsequent with this deal the Burlington Joint Venture between Enertopia and Lexaria which was entered into on May 27, 2014 has been terminated due to the pending sale of the project. The Enertopia and Lexaria Master Joint Venture Agreement entered into on March 5, 2014 is still in good standing as both companies continue to look at synergistic opportunities to increase shareholder value.


After thorough examination of the Medical Marihuana industry in Canada and current participants within the sector, it is apparent that raising capital to push projects forward is not currently in the best interests of the Company. Therefore, the Company and The Green Canvas have mutually agreed to terminate their Joint Venture and 6,400,000 shares of Enertopia held in escrow with respect to The Green Canvas Joint Venture will be returned back to corporate treasury and cancelled.


Enertopia is and will continue to be an advocate for medical cannabis for patients and applauds the landmark Supreme Court of Canada ruling on June 11, 2015. This ruling upheld the rights of legal MMAR and MMPR medical cannabis patients in Canada. The unanimous ruling allows valid legal medical patients to choose how they want to administer medical cannabis by the method that is best suited to their medical condition and body absorption. This is looks to be a very positive development for the Canadian medical marihuana sector going forward, as the Federal Government will have to modify or implement a program for the administration of other forms of medical cannabis consumption.


Enertopia will continue to look for opportunities in the MMJ and other sectors that offer the best return for all stakeholders with the least amount of dilution to the Company. The Company looks forward to utilizing its learned knowledge in the MMJ sector and will continue on its path of becoming a licensed producer.


“The Company has completed two milestones in building a stable foundation with its ownership of 1,000,000 shares in Lexaria Corp which has just filed PCT for patent pending bio technologies and the potential of approximately $750,000 in future payments from the Burlington application,” Stated President Robert McAllister


The Company looks forward to providing information via social media, website and press releases as news and events become known over the coming weeks.


About Enertopia


We are a company with the mission to empower people with a better way of living through healthy lifestyle choices in helping you live your life your way. Our core values of honesty, integrity, and commitment help to define our corporate practices and demonstrate our dedication in helping individuals whether they are encountering health issues based on age, diet or have suffered a traumatic physical, mental or an emotional event.


Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412


This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Company will receive any milestone payments from the sale of Thor Pharma and the Burlington MMPR application, or that the 1,000,000 shares of Lexaria Corp will have any meaningful impact on the Company or the Company will be able to obtain future financings or a license under the MMPR program.


The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release




















Tags: , , , , , 
 Posted in All Recent Posts, Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Canadian Medical Marihuana Update









 Medical marijuana includes cookies, brownies, oils and tea rules Supreme Court




Posted by AGORACOM-JC
at 11:33 AM on Thursday, June 11th, 2015 


























The Supreme Court of Canada has ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.














DARRYL DYCK / THE CANADIAN PRESS


Cannabis-infused peanut butter cookies are displayed for sale at a Weeds Glass and Gifts medical marijuana dispensary in downtown Vancouver, B.C.












By: The Canadian Press, Published on Thu Jun 11 2015










OTTAWA—The Supreme Court of Canada says medical marijuana can include products other than dried pot, such as cannabis-infused cookies brownies, oils and tea.






The court has rejected an appeal by the federal government of a lower court ruling that medical marijuana users have a right to a range of products containing the drug.






In a 7-0 decision, the court ruled that limiting medical consumption to dried marijuana infringes on liberty protections under the Charter of Rights.






Current federal regulations stipulate that authorized users of physician-prescribed cannabis can only consume dried marijuana.






The case stems from the arrest in 2009 of Owen Smith, former head baker for the Cannabis Buyers Club of Canada, who was charged after police found more than 200 pot cookies and cannabis-infused olive oil and grapeseed oil in his Victoria apartment.





























Tags: , , , , 
 Posted in All Recent Posts, Enertopia, Enertopia Corp., Medical Marijuana Stocks, Next Gen, Supreme Pharmaceuticals Inc | Comments Off on Medical marijuana includes cookies, brownies, oils and tea rules Supreme Court









 Private insurer covers medical marijuana costs




Posted by AGORACOM-JC
at 11:18 AM on Monday, March 23rd, 2015 








A university student’s medical marijuana is being paid for by his private insurance company – a feat some industry insiders say is unprecedented.










Sun Life Financial is covering the medical marijuana costs of University of Waterloo student Jonathan Zaid.




Peter Power / For The Toronto Star


Sun Life Financial is covering the medical marijuana costs of University of Waterloo student Jonathan Zaid.












By: Isabel Teotonio Living reporter, Published on Fri Mar 20 2015








After a hard-fought battle, Jonathan Zaid’s medical marijuana is being paid for by his private insurance company — a feat some industry insiders say is unprecedented.






Now, the third-year University of Waterloo student, who suffers from a rare illness called new daily persistent headache, is hoping this victory clears the way for other patients seeking coverage for cannabis.






“I had to fight a lot of battles to get to where I am,” says the 22-year-old Toronto native. “My persistence paid off in the end.”






Last summer, Zaid submitted a claim for his medical marijuana to insurance giant Sun Life Financial. It was denied. Insurance companies don’t typically pay for cannabis. Although medical marijuana is federally regulated it is not an approved medicine in Canada and has no Drug Identification Number (DIN).






But Zaid wouldn’t give up. He was frustrated with always asking his parents for money to buy his “medicine” from a licensed producer. And after trying 48 different drugs over the years, only marijuana eased his chronic headaches. He figured it should be recognized as prescription medication — after all, it was prescribed by a doctor.






Zaid, the son of a retired lawyer, presented research on his condition and the medicinal benefits of marijuana to an oversight committee of the University of Waterloo student union, which administers the student health plan. It would be up to the student association as the plan’s sponsor — that’s the organization or employer that sets up the healthcare plan — to ask Sun Life to make an exception.






Student Ben Balfour, who is part of the committee, says there was initial concern about approving Zaid’s request because it was their first time dealing with marijuana.






“We were testing the waters and we didn’t know how people would react,” says Balfour, vice-president of operations and finance for the Federation of Students.






But after much back and forth between Zaid and the committee, which includes a physician, his request was approved in December. The committee found Zaid’s evidence to be persuasive, that the plan could support the cost and that having Zaid’s medicinal marijuana covered would positively impact his academic success and wellbeing.






“It’s really something new and I was very excited to be a part of it,” says Balfour. “I’m just very glad that we were able to figure it all out in the end.”






Sun Life issued a cheque reimbursing Zaid for nearly $3,000, covering the costs of cannabis and a $750 vaporizer — he gave the money to his parents. His triumph doesn’t mean other U of W students are automatically covered for medicinal marijuana, which has not been added to the formulary. But, it opens the door for others to follow his lead and go through the same process.






Sun Life can’t comment on the specifics of this case or benefit plan. While medical marijuana is not an eligible expense in its standard benefit plans, Sun Life does consider requests for exceptions if directed by the organization or employer responsible for the benefit plan. Insurance behemoth Manulife has a similar policy, but is not aware of having made any exception for medical cannabis.






There are cases of the government paying for medical marijuana: Ontario’s Workplace Safety and Insurance Board (WSIB), Quebec’s Commission de la santé et de la sécurité du travail (CSST), and Veterans Affairs, via






Medavie Blue Cross, have covered cannabis costs.






It’s unclear how unusual Zaid’s case is because Sun Life will not comment on if other patients, or benefit plans, have requested similar coverage.






And, it’s unknown what effect, if any, it will have on future claims for cannabis made to insurers, says Wendy Hope, vice-president of external relations for the Canadian Life and Health Insurance Association. Hope says this sort of claim is not unprecedented and that some private insurers have, for some time now, been reimbursing costs for medical marijuana through health spending accounts – although it is rare.






Zaid attributes his success to not giving up, but realizes few patients have the strength, or know-how, to accomplish what he did.






“We’re talking about very sick people and lots of them don’t have the resources to spend in order to fight for fair access,” says Zaid. His advocacy work prompted him to launch the non-profit Canadians for Fair Access to Medical Marijuana and he now sits on the patient advisory board of licensed producer Bedrocan Canada.






Sarah Smith, who pays $180 a month out-of-pocket for medical cannabis after being denied by her private insurer, hopes Zaid’s case will impact insurance practices. Unlike Zaid, she says, “I didn’t have the fight in me.”






“I’m optimistic this will help open the eyes of insurance companies that not all prescriptions are pills, sometimes it’s an herb,” says Smith, not her real name. “They shouldn’t be differentiating — a prescription is a prescription.”






Zaid’s case is precedent-setting, says Marc Wayne, CEO of Bedrocan Canada and chair of the Canadian Medical Cannabis Industry Association.






“It’s an example of the way this type of thing has to work. . . Insurance companies aren’t going to come out and say, ‘We’re going to cover medicinal cannabis for everybody.’ It’s a case-by-case approach and hopefully it will reach a tipping point.”


Source: http://www.thestar.com/life/health_wellness/2015/03/20/private-insurer-covers-medical-marijuana-costs.html












Tags: , , , , 
 Posted in Medical Marijuana Stocks | Comments Off on Private insurer covers medical marijuana costs









 Enertopia Announces V-LOVE ™ For Women




Posted by AGORACOM-JC
at 8:07 AM on Monday, February 9th, 2015 








VANCOUVER, BC / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce the launch of a new product line for women’s sexual health. This is the Company’s first step in its new initiatives and strategic plan in alternative health and wellness sector. V-LoveTM for Women is a desire gel and will be available for sale in Canada soon and will be available for sale in the USA later this year. The Company owns 100% of the product and how it will roll out the product to market.


The Company has entered into a partnership with Maureen McGrath, host of the popular Sunday Night Sex Show on CKNW radio, to raise awareness and continue to educate the public with her knowledge base and expertise in Men’s and Women’s sexual health. Maureen McGrath is a registered nurse in the field of sexual health for men and women.


Enertopia will be announcing additional information on its product lines and business plan in the immediate future as it launches its products in a growing sexual health market with industry sales that have surpassed $20 billion dollars and specifically over $1.2 billion dollars last year in the lubrication market alone. The first product launch V-Love will be in Canada and available in the United States in the coming months. The second product launch will be the V-LoveTM infused with CBD from industrial hemp oil made and only available in the USA. Our goal is to begin producing cash flows from these initiatives as soon as possible; focused on the immediate opportunities in the CBD-sectors derived from already-legal hemp. CBDs (Cannabidiols) have been found by many researchers to have antioxidant properties and are able to be infused into a number of products.


The US Federal government, through the US Department of Health and Human Services, owns US Patent #6,630,507, which among other things, claims that


“Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases.”


Maureen is a clinician in addition to being well known and sought after guest lecturer in the field of sexual health for men and women. She has a special interest in women’s sexual desire. This aligns with our vision for natural based healing options. Maureen’s passion over the past two decades of learning and responding to her patient’s needs has led to natural based healing as a clear option for better health in many instances. She is in private practice both in North Vancouver and at Cross Roads Clinic in Vancouver where she see patients with sexual health issues.


“I am excited at the prospect of raising awareness and providing options about such an important subject as female and male sexuality. Providing evidence based strategies to patients is the cornerstone to getting people to feel comfortable discussing a subject that until now has been deemed very sensitive by many. Getting couples to live their life, their way is what this is all about,” said Maureen McGrath, RN and Sexpert.


During the Company’s research in the Medical Marijuana field and other parallel industries it has become apparent that proper education is paramount for people to regain their lives. “Everyone has to be their own personal advocate for better health.” Stated President / CEO Robert McAllister


For further information please visit the company’s updated website www.enertopia.com that has incorporated today’s news and the new Health Canada guidelines for Licensed Producers and those in the process of becoming a licensed producer on what can be shown on one’s website or printed materials.


About Enertopia


Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call Robert McAllister, the President: (250) 765-6412


This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential and financing of its medical marihuana projects, evaluation and sale of sexual creams and other items, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that Maureen McGrath’s outreach or the V-LoveTM sexual gel will have any meaningful impact on the Company or the Company will be able to obtain future financings.


The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release


Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks




Tags: , , , , , 
 Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Announces V-LOVE ™ For Women






« Older Entries